- Home
- EMX vs LAB Comparison
EMX vs LAB Comparison
Compare EMX & LAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EMX
- LAB
- Stock Information
- Founded
- EMX N/A
- LAB 1999
- Country
- EMX Canada
- LAB United States
- Employees
- EMX N/A
- LAB N/A
- Industry
- EMX
- LAB Biotechnology: Laboratory Analytical Instruments
- Sector
- EMX
- LAB Industrials
- Exchange
- EMX Nasdaq
- LAB Nasdaq
- Market Cap
- EMX 461.8M
- LAB 504.2M
- IPO Year
- EMX N/A
- LAB 2011
- Fundamental
- Price
- EMX $4.14
- LAB $1.15
- Analyst Decision
- EMX Strong Buy
- LAB Buy
- Analyst Count
- EMX 2
- LAB 2
- Target Price
- EMX $5.38
- LAB $2.50
- AVG Volume (30 Days)
- EMX 907.3K
- LAB 1.6M
- Earning Date
- EMX 11-07-2025
- LAB 11-04-2025
- Dividend Yield
- EMX N/A
- LAB N/A
- EPS Growth
- EMX N/A
- LAB N/A
- EPS
- EMX 0.04
- LAB N/A
- Revenue
- EMX $29,864,000.00
- LAB $172,271,000.00
- Revenue This Year
- EMX $11.08
- LAB N/A
- Revenue Next Year
- EMX $3.72
- LAB N/A
- P/E Ratio
- EMX $92.47
- LAB N/A
- Revenue Growth
- EMX N/A
- LAB 76.33
- 52 Week Low
- EMX $1.65
- LAB $0.92
- 52 Week High
- EMX $5.39
- LAB $2.32
- Technical
- Relative Strength Index (RSI)
- EMX 42.43
- LAB 37.44
- Support Level
- EMX $3.95
- LAB $1.26
- Resistance Level
- EMX $4.29
- LAB $1.44
- Average True Range (ATR)
- EMX 0.27
- LAB 0.09
- MACD
- EMX -0.11
- LAB -0.02
- Stochastic Oscillator
- EMX 15.32
- LAB 8.57
About EMX EMX Royalty Corporation (Canada)
EMX Royalty Corp and its subsidiaries operate as a royalty and prospect generator engaged in exploring for and generating royalties from, metals and minerals properties. The company is a precious, and base metals royalty company. The Company augments royalty generation with royalty acquisitions and strategic investments. EMX's royalty and mineral property portfolio consists of properties in North America, Europe, Turkiye, Latin America, Morocco and Australia.
About LAB Standard BioTools Inc.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.